Please Wait.....
Report
Custom Antibody Services Market? By Service (Antibody Development, Antibody Production and Purification, Antibody Fragmentation and Labeling) , By Type (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies, Others) By Source (Mice, Rabbit, Others) By Application (Oncology, Infectious Diseases, Neurology, Immunology, Cardiovascular Diseases, Others) By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 233 Pages I Allied Market Research
Custom Antibody Services Market
The custom antibody services marketwas valued at $0.6 billion in 2023 and is projected to reach $1.4 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.
Custom antibody services involve producing distinguished antibodies as per user requirements. The antibodies are specifically tailored for diagnostic, research, and therapeutic purposes. A key benefit of utilizing custom antibody services is the attainability of specificity in antibodies against antigens, resulting in improved & reliable experimental results. In addition, the flexibility of integrating different modifications into the antibodies attracts clients to benefit from the custom antibody services.
Increase in the popularity of personalized medicine for targeted therapies is rising the adoption of custom antibody services in the healthcare field. In addition, with surging expenditure in the pharmaceutical and biotech sectors for the strengthening of their R&D activities, the growth of the market is being driven considerably. The future of the custom antibody services market is anticipated to be redefined by recombinant technology and novel antibody trends. AI and ML algorithm are poised to assist in the designing of antibodies and develop next-generational antibodies such as single domain antibodies, bispecific antibodies, and antibody fragments.
However, the high cost of antibody production and extended development time hamper the growth of the custom antibody services market. In addition, the quality control measures and validation processes established for the approval of antibodies are highly rigorous and time-consuming. Efficient compliance with such standards delays the growth of the market. Contrarily, with rising investments on drug development and R&D, the custom antibody services market is anticipated to witness several lucrative growth opportunities. According to Statista, a global data and business intelligence platform, the U.S. spent an estimated amount of $603 billion on medicine in 2022. Furthermore, pharma companies in the U.S. spend approximately 21% of their revenue on R&D activities. Such expenditures indicate a promising future for the custom antibody services market.
Segment Review
The custom antibody services marketis segmented into service, type, source, application, end user, and region. On the basis of service, the market is divided into antibody development, antibody production & purification, and antibody fragmentation & labeling. As per type, it is classifiedinto monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others. Depending on source, it is categorized into mice, rabbit, and others. According to application, it is divided into oncology, infectious diseases, neurology, immunology, cardiovascular diseases, and others. By end user, it is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of service, the antibody development segment dominated the market in 2023.
As per type, the monoclonal antibodies segment was the major shareholder of the market in 2023.
Depending on source, the rabbit segment held a high share in the market in 2023.
According to application, the infectious diseases segment accounted for a high share in the market in 2023.
By end user, the pharmaceutical & biotechnology companies segment acquired a high stake in the market in 2023.
Region wise, North America was the highest revenue generator in 2023.
Competition Analysis
The major players of the global custom antibody services marketare Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., Sino Biological, Inc., Bio-Rad Laboratories, Inc, Kaneka Eurogentec S.A., YenZym Antibodies, LLC., OriGene Technologies, Inc., Laboratory Corporation of America Holdings., and GenScript. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Service
- Antibody Development
- Antibody Production and Purification
- Antibody Fragmentation and Labeling
By Type
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Antibodies
- Others
By Source
- Mice
- Rabbit
- Others
By Application
- Oncology
- Infectious Diseases
- Neurology
- Immunology
- Cardiovascular Diseases
- Others
By End User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Agilent Technologies, Inc.
- Sino Biological, Inc.
- Bio-Rad Laboratories, Inc
- Kaneka Eurogentec S.A.
- YenZym Antibodies, LLC.
- OriGene Technologies, Inc.
- Laboratory Corporation of America Holdings.
- GenScript
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: CYTOTOXIC DRUG MARKET, BY DRUG TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Drug Type
4.2. Alkylating Agents
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Antitumor Antibiotics
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Antimetabolites
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Plant Alkaloids
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
CHAPTER 5: CYTOTOXIC DRUG MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Breast Cancer
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Prostate Cancer
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Lung Cancer
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Pancreatic Cancer
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
5.6. Others
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Size and Forecast, By Region
5.6.3. Market Share Analysis, By Country
CHAPTER 6: CYTOTOXIC DRUG MARKET, BY ROUTE OF ADMINISTRATION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Route of Administration
6.2. Oral
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Parenteral
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
CHAPTER 7: CYTOTOXIC DRUG MARKET, BY DISTRIBUTION CHANNEL
7.1. Market Overview
7.1.1 Market Size and Forecast, By Distribution Channel
7.2. Hospital Pharmacies
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Drug Stores And Retail Pharmacies
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
7.4. Online Providers
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, By Region
7.4.3. Market Share Analysis, By Country
CHAPTER 8: CYTOTOXIC DRUG MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Drug Type
8.2.3. Market Size and Forecast, By Application
8.2.4. Market Size and Forecast, By Route of Administration
8.2.5. Market Size and Forecast, By Distribution Channel
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Cytotoxic Drug Market
8.2.7.1. Market Size and Forecast, By Drug Type
8.2.7.2. Market Size and Forecast, By Application
8.2.7.3. Market Size and Forecast, By Route of Administration
8.2.7.4. Market Size and Forecast, By Distribution Channel
8.2.8. Canada Cytotoxic Drug Market
8.2.8.1. Market Size and Forecast, By Drug Type
8.2.8.2. Market Size and Forecast, By Application
8.2.8.3. Market Size and Forecast, By Route of Administration
8.2.8.4. Market Size and Forecast, By Distribution Channel
8.2.9. Mexico Cytotoxic Drug Market
8.2.9.1. Market Size and Forecast, By Drug Type
8.2.9.2. Market Size and Forecast, By Application
8.2.9.3. Market Size and Forecast, By Route of Administration
8.2.9.4. Market Size and Forecast, By Distribution Channel
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Drug Type
8.3.3. Market Size and Forecast, By Application
8.3.4. Market Size and Forecast, By Route of Administration
8.3.5. Market Size and Forecast, By Distribution Channel
8.3.6. Market Size and Forecast, By Country
8.3.7. Germany Cytotoxic Drug Market
8.3.7.1. Market Size and Forecast, By Drug Type
8.3.7.2. Market Size and Forecast, By Application
8.3.7.3. Market Size and Forecast, By Route of Administration
8.3.7.4. Market Size and Forecast, By Distribution Channel
8.3.8. France Cytotoxic Drug Market
8.3.8.1. Market Size and Forecast, By Drug Type
8.3.8.2. Market Size and Forecast, By Application
8.3.8.3. Market Size and Forecast, By Route of Administration
8.3.8.4. Market Size and Forecast, By Distribution Channel
8.3.9. UK Cytotoxic Drug Market
8.3.9.1. Market Size and Forecast, By Drug Type
8.3.9.2. Market Size and Forecast, By Application
8.3.9.3. Market Size and Forecast, By Route of Administration
8.3.9.4. Market Size and Forecast, By Distribution Channel
8.3.10. Italy Cytotoxic Drug Market
8.3.10.1. Market Size and Forecast, By Drug Type
8.3.10.2. Market Size and Forecast, By Application
8.3.10.3. Market Size and Forecast, By Route of Administration
8.3.10.4. Market Size and Forecast, By Distribution Channel
8.3.11. Spain Cytotoxic Drug Market
8.3.11.1. Market Size and Forecast, By Drug Type
8.3.11.2. Market Size and Forecast, By Application
8.3.11.3. Market Size and Forecast, By Route of Administration
8.3.11.4. Market Size and Forecast, By Distribution Channel
8.3.12. Rest of Europe Cytotoxic Drug Market
8.3.12.1. Market Size and Forecast, By Drug Type
8.3.12.2. Market Size and Forecast, By Application
8.3.12.3. Market Size and Forecast, By Route of Administration
8.3.12.4. Market Size and Forecast, By Distribution Channel
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Drug Type
8.4.3. Market Size and Forecast, By Application
8.4.4. Market Size and Forecast, By Route of Administration
8.4.5. Market Size and Forecast, By Distribution Channel
8.4.6. Market Size and Forecast, By Country
8.4.7. Japan Cytotoxic Drug Market
8.4.7.1. Market Size and Forecast, By Drug Type
8.4.7.2. Market Size and Forecast, By Application
8.4.7.3. Market Size and Forecast, By Route of Administration
8.4.7.4. Market Size and Forecast, By Distribution Channel
8.4.8. China Cytotoxic Drug Market
8.4.8.1. Market Size and Forecast, By Drug Type
8.4.8.2. Market Size and Forecast, By Application
8.4.8.3. Market Size and Forecast, By Route of Administration
8.4.8.4. Market Size and Forecast, By Distribution Channel
8.4.9. India Cytotoxic Drug Market
8.4.9.1. Market Size and Forecast, By Drug Type
8.4.9.2. Market Size and Forecast, By Application
8.4.9.3. Market Size and Forecast, By Route of Administration
8.4.9.4. Market Size and Forecast, By Distribution Channel
8.4.10. Australia Cytotoxic Drug Market
8.4.10.1. Market Size and Forecast, By Drug Type
8.4.10.2. Market Size and Forecast, By Application
8.4.10.3. Market Size and Forecast, By Route of Administration
8.4.10.4. Market Size and Forecast, By Distribution Channel
8.4.11. South Korea Cytotoxic Drug Market
8.4.11.1. Market Size and Forecast, By Drug Type
8.4.11.2. Market Size and Forecast, By Application
8.4.11.3. Market Size and Forecast, By Route of Administration
8.4.11.4. Market Size and Forecast, By Distribution Channel
8.4.12. Rest of Asia-Pacific Cytotoxic Drug Market
8.4.12.1. Market Size and Forecast, By Drug Type
8.4.12.2. Market Size and Forecast, By Application
8.4.12.3. Market Size and Forecast, By Route of Administration
8.4.12.4. Market Size and Forecast, By Distribution Channel
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Drug Type
8.5.3. Market Size and Forecast, By Application
8.5.4. Market Size and Forecast, By Route of Administration
8.5.5. Market Size and Forecast, By Distribution Channel
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Cytotoxic Drug Market
8.5.7.1. Market Size and Forecast, By Drug Type
8.5.7.2. Market Size and Forecast, By Application
8.5.7.3. Market Size and Forecast, By Route of Administration
8.5.7.4. Market Size and Forecast, By Distribution Channel
8.5.8. Saudi Arabia Cytotoxic Drug Market
8.5.8.1. Market Size and Forecast, By Drug Type
8.5.8.2. Market Size and Forecast, By Application
8.5.8.3. Market Size and Forecast, By Route of Administration
8.5.8.4. Market Size and Forecast, By Distribution Channel
8.5.9. South Africa Cytotoxic Drug Market
8.5.9.1. Market Size and Forecast, By Drug Type
8.5.9.2. Market Size and Forecast, By Application
8.5.9.3. Market Size and Forecast, By Route of Administration
8.5.9.4. Market Size and Forecast, By Distribution Channel
8.5.10. Rest of LAMEA Cytotoxic Drug Market
8.5.10.1. Market Size and Forecast, By Drug Type
8.5.10.2. Market Size and Forecast, By Application
8.5.10.3. Market Size and Forecast, By Route of Administration
8.5.10.4. Market Size and Forecast, By Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Baxter
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Cipla Ltd
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. Eli Lilly And Company
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. Fresenius Kabi AG
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Johnson And Johnson
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Novartis AG
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. Viatris Inc.
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Pfizer Inc.
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Sun Pharmaceutical Industries Ltd.
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Teva Pharmaceutical Industries Ltd.
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 2. CUSTOM ANTIBODY SERVICES MARKET FOR ANTIBODY DEVELOPMENT, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. CUSTOM ANTIBODY SERVICES MARKET FOR ANTIBODY PRODUCTION AND PURIFICATION, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. CUSTOM ANTIBODY SERVICES MARKET FOR ANTIBODY FRAGMENTATION AND LABELING, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. GLOBAL CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 6. CUSTOM ANTIBODY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. CUSTOM ANTIBODY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. CUSTOM ANTIBODY SERVICES MARKET FOR RECOMBINANT ANTIBODIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. CUSTOM ANTIBODY SERVICES MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. GLOBAL CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 11. CUSTOM ANTIBODY SERVICES MARKET FOR MICE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. CUSTOM ANTIBODY SERVICES MARKET FOR RABBIT, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. CUSTOM ANTIBODY SERVICES MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. GLOBAL CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 15. CUSTOM ANTIBODY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. CUSTOM ANTIBODY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 17. CUSTOM ANTIBODY SERVICES MARKET FOR NEUROLOGY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 18. CUSTOM ANTIBODY SERVICES MARKET FOR IMMUNOLOGY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 19. CUSTOM ANTIBODY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 20. CUSTOM ANTIBODY SERVICES MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 21. GLOBAL CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 22. CUSTOM ANTIBODY SERVICES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 23. CUSTOM ANTIBODY SERVICES MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 24. CUSTOM ANTIBODY SERVICES MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 25. CUSTOM ANTIBODY SERVICES MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 26. NORTH AMERICA CUSTOM ANTIBODY SERVICES MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 27. NORTH AMERICA CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 28. NORTH AMERICA CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 29. NORTH AMERICA CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 30. NORTH AMERICA CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 31. NORTH AMERICA CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 32. U.S. CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 33. U.S. CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 34. U.S. CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 35. U.S. CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 36. U.S. CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 37. CANADA CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 38. CANADA CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 39. CANADA CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 40. CANADA CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 41. CANADA CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 42. MEXICO CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 43. MEXICO CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 44. MEXICO CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 45. MEXICO CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 46. MEXICO CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 47. EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 48. EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 49. EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 50. EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 51. EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 52. EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 53. GERMANY CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 54. GERMANY CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 55. GERMANY CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 56. GERMANY CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 57. GERMANY CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 58. FRANCE CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 59. FRANCE CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 60. FRANCE CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 61. FRANCE CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 62. FRANCE CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 63. UK CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 64. UK CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 65. UK CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 66. UK CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 67. UK CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 68. ITALY CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 69. ITALY CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 70. ITALY CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 71. ITALY CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 72. ITALY CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 73. SPAIN CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 74. SPAIN CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 75. SPAIN CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 76. SPAIN CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 77. SPAIN CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 78. REST OF EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 79. REST OF EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 80. REST OF EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 81. REST OF EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 82. REST OF EUROPE CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 83. ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 84. ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 85. ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 86. ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 87. ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 88. ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 89. JAPAN CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 90. JAPAN CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 91. JAPAN CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 92. JAPAN CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 93. JAPAN CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 94. CHINA CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 95. CHINA CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 96. CHINA CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 97. CHINA CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 98. CHINA CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 99. INDIA CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 100. INDIA CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 101. INDIA CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 102. INDIA CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 103. INDIA CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 104. AUSTRALIA CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 105. AUSTRALIA CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 106. AUSTRALIA CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 107. AUSTRALIA CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 108. AUSTRALIA CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 109. SOUTH KOREA CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 110. SOUTH KOREA CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 111. SOUTH KOREA CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 112. SOUTH KOREA CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 113. SOUTH KOREA CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 114. REST OF ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 115. REST OF ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 116. REST OF ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 117. REST OF ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 118. REST OF ASIA-PACIFIC CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 119. LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 120. LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 121. LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 122. LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 123. LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 124. LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 125. BRAZIL CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 126. BRAZIL CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 127. BRAZIL CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 128. BRAZIL CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 129. BRAZIL CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 130. SAUDI ARABIA CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 131. SAUDI ARABIA CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 132. SAUDI ARABIA CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 133. SAUDI ARABIA CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 134. SAUDI ARABIA CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 135. SOUTH AFRICA CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 136. SOUTH AFRICA CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 137. SOUTH AFRICA CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 138. SOUTH AFRICA CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 139. SOUTH AFRICA CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 140. REST OF LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 141. REST OF LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 142. REST OF LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY SOURCE, 2024 - 2033 ($BILLION)
TABLE 143. REST OF LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 144. REST OF LAMEA CUSTOM ANTIBODY SERVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 145. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 146. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 147. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
TABLE 148. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 149. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 150. MERCK KGAA: KEY EXECUTIVES
TABLE 151. MERCK KGAA: COMPANY SNAPSHOT
TABLE 152. MERCK KGAA: OPERATING SEGMENTS
TABLE 153. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 154. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 155. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 156. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 157. AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
TABLE 158. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 159. AGILENT TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 160. SINO BIOLOGICAL, INC.: KEY EXECUTIVES
TABLE 161. SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT
TABLE 162. SINO BIOLOGICAL, INC.: OPERATING SEGMENTS
TABLE 163. SINO BIOLOGICAL, INC.: PRODUCT PORTFOLIO
TABLE 164. SINO BIOLOGICAL, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 165. BIO-RAD LABORATORIES, INC: KEY EXECUTIVES
TABLE 166. BIO-RAD LABORATORIES, INC: COMPANY SNAPSHOT
TABLE 167. BIO-RAD LABORATORIES, INC: OPERATING SEGMENTS
TABLE 168. BIO-RAD LABORATORIES, INC: PRODUCT PORTFOLIO
TABLE 169. BIO-RAD LABORATORIES, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 170. KANEKA EUROGENTEC S.A.: KEY EXECUTIVES
TABLE 171. KANEKA EUROGENTEC S.A.: COMPANY SNAPSHOT
TABLE 172. KANEKA EUROGENTEC S.A.: OPERATING SEGMENTS
TABLE 173. KANEKA EUROGENTEC S.A.: PRODUCT PORTFOLIO
TABLE 174. KANEKA EUROGENTEC S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 175. YENZYM ANTIBODIES, LLC.: KEY EXECUTIVES
TABLE 176. YENZYM ANTIBODIES, LLC.: COMPANY SNAPSHOT
TABLE 177. YENZYM ANTIBODIES, LLC.: OPERATING SEGMENTS
TABLE 178. YENZYM ANTIBODIES, LLC.: PRODUCT PORTFOLIO
TABLE 179. YENZYM ANTIBODIES, LLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 180. ORIGENE TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 181. ORIGENE TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 182. ORIGENE TECHNOLOGIES, INC.: OPERATING SEGMENTS
TABLE 183. ORIGENE TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 184. ORIGENE TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 185. LABORATORY CORPORATION OF AMERICA HOLDINGS.: KEY EXECUTIVES
TABLE 186. LABORATORY CORPORATION OF AMERICA HOLDINGS.: COMPANY SNAPSHOT
TABLE 187. LABORATORY CORPORATION OF AMERICA HOLDINGS.: OPERATING SEGMENTS
TABLE 188. LABORATORY CORPORATION OF AMERICA HOLDINGS.: PRODUCT PORTFOLIO
TABLE 189. LABORATORY CORPORATION OF AMERICA HOLDINGS.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 190. GENSCRIPT: KEY EXECUTIVES
TABLE 191. GENSCRIPT: COMPANY SNAPSHOT
TABLE 192. GENSCRIPT: OPERATING SEGMENTS
TABLE 193. GENSCRIPT: PRODUCT PORTFOLIO
TABLE 194. GENSCRIPT: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL CUSTOM ANTIBODY SERVICES MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF CUSTOM ANTIBODY SERVICES MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN CUSTOM ANTIBODY SERVICES MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCUSTOM ANTIBODY SERVICES MARKET
FIGURE 10. GLOBAL CUSTOM ANTIBODY SERVICES MARKET SEGMENTATION, BY SERVICE
FIGURE 11. CUSTOM ANTIBODY SERVICES MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. CUSTOM ANTIBODY SERVICES MARKET FOR ANTIBODY PRODUCTION AND PURIFICATION, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. CUSTOM ANTIBODY SERVICES MARKET FOR ANTIBODY FRAGMENTATION AND LABELING, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. GLOBAL CUSTOM ANTIBODY SERVICES MARKET SEGMENTATION, BY TYPE
FIGURE 15. CUSTOM ANTIBODY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. CUSTOM ANTIBODY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. CUSTOM ANTIBODY SERVICES MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. CUSTOM ANTIBODY SERVICES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. GLOBAL CUSTOM ANTIBODY SERVICES MARKET SEGMENTATION, BY SOURCE
FIGURE 20. CUSTOM ANTIBODY SERVICES MARKET FOR MICE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. CUSTOM ANTIBODY SERVICES MARKET FOR RABBIT, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. CUSTOM ANTIBODY SERVICES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. GLOBAL CUSTOM ANTIBODY SERVICES MARKET SEGMENTATION, BY APPLICATION
FIGURE 24. CUSTOM ANTIBODY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. CUSTOM ANTIBODY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 26. CUSTOM ANTIBODY SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 27. CUSTOM ANTIBODY SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 28. CUSTOM ANTIBODY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 29. CUSTOM ANTIBODY SERVICES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 30. GLOBAL CUSTOM ANTIBODY SERVICES MARKET SEGMENTATION, BY END USER
FIGURE 31. CUSTOM ANTIBODY SERVICES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 32. CUSTOM ANTIBODY SERVICES MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 33. CUSTOM ANTIBODY SERVICES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 34. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 35. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 36. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 37. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 38. COMPETITIVE DASHBOARD
FIGURE 39. COMPETITIVE HEATMAP: CUSTOM ANTIBODY SERVICES MARKET
FIGURE 40. TOP PLAYER POSITIONING, 2023
FIGURE 41. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 42. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. MERCK KGAA: NET SALES, 2021-2023 ($BILLION)
FIGURE 45. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. MERCK KGAA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. AGILENT TECHNOLOGIES, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 48. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 50. SINO BIOLOGICAL, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 51. SINO BIOLOGICAL, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 52. SINO BIOLOGICAL, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 53. BIO-RAD LABORATORIES, INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 54. BIO-RAD LABORATORIES, INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 55. BIO-RAD LABORATORIES, INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 56. KANEKA EUROGENTEC S.A.: NET SALES, 2021-2023 ($BILLION)
FIGURE 57. KANEKA EUROGENTEC S.A.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 58. KANEKA EUROGENTEC S.A.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 59. YENZYM ANTIBODIES, LLC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 60. YENZYM ANTIBODIES, LLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 61. YENZYM ANTIBODIES, LLC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 62. ORIGENE TECHNOLOGIES, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 63. ORIGENE TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 64. ORIGENE TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 65. LABORATORY CORPORATION OF AMERICA HOLDINGS.: NET SALES, 2021-2023 ($BILLION)
FIGURE 66. LABORATORY CORPORATION OF AMERICA HOLDINGS.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 67. LABORATORY CORPORATION OF AMERICA HOLDINGS.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 68. GENSCRIPT: NET SALES, 2021-2023 ($BILLION)
FIGURE 69. GENSCRIPT: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 70. GENSCRIPT: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security